Roche Confident But Cautious On Alzheimer's Hopeful
Key Gantenerumab Readout Next Year
The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.
